Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):40–45. doi: 10.1097/PAI.0000000000000500

Figure 2.

Figure 2

Two malignant melanomas, one with low tumor cell content, second with prominent stromal cells and lymphoid elements (LCA staining). Next generation sequencing revealing NRAS c.182A>G substitution predicted to cause NRAS Q61R mutation.